Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
228.39
-5.81 (-2.48%)
At close: Jun 18, 2026, 4:00 PM EDT
228.64
+0.25 (0.11%)
After-hours: Jun 18, 2026, 7:59 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,200 employees as of December 31, 2025. The number of employees increased by 100 or 0.07% compared to the previous year.
Employees
138,200
Change (1Y)
100
Growth (1Y)
0.07%
Revenue / Employee
$697,265
Profits / Employee
$152,243
Market Cap
549.78B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 138,200 | 100 | 0.07% |
| Dec 31, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Dec 31, 2022 | 152,700 | 11,000 | 7.76% |
| Dec 31, 2021 | 141,700 | 7,200 | 5.35% |
| Dec 31, 2020 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | 132,200 | -2,900 | -2.15% |
| Dec 30, 2018 | 135,100 | 1,100 | 0.82% |
| Dec 31, 2017 | 134,000 | 7,600 | 6.01% |
| Dec 31, 2016 | 126,400 | -700 | -0.55% |
| Dec 31, 2015 | 127,100 | 600 | 0.47% |
| Dec 28, 2014 | 126,500 | -1,600 | -1.25% |
| Dec 29, 2013 | 128,100 | 500 | 0.39% |
| Dec 30, 2012 | 127,600 | 9,700 | 8.23% |
| Dec 31, 2011 | 117,900 | 3,900 | 3.42% |
| Dec 31, 2010 | 114,000 | -1,500 | -1.30% |
| Dec 31, 2009 | 115,500 | -3,200 | -2.70% |
| Dec 28, 2008 | 118,700 | -500 | -0.42% |
| Dec 30, 2007 | 119,200 | -3,000 | -2.45% |
| Dec 31, 2006 | 122,200 | 6,600 | 5.71% |
| Dec 31, 2005 | 115,600 | 5,600 | 5.09% |
| Dec 31, 2004 | 110,000 | -1,000 | -0.90% |
| Dec 28, 2003 | 111,000 | 3,000 | 2.78% |
| Dec 29, 2002 | 108,000 | 6,000 | 5.88% |
| Dec 30, 2001 | 102,000 | 1,000 | 0.99% |
| Dec 31, 2000 | 101,000 | 3,200 | 3.27% |
| Dec 31, 1999 | 97,800 | 4,700 | 5.05% |
| Dec 31, 1998 | 93,100 | 2,600 | 2.87% |
| Dec 28, 1997 | 90,500 | 1,200 | 1.34% |
| Dec 29, 1996 | 89,300 | 7,000 | 8.51% |
| Dec 31, 1995 | 82,300 | 800 | 0.98% |
| Dec 31, 1994 | 81,500 | -100 | -0.12% |
| Dec 31, 1993 | 81,600 | -3,300 | -3.89% |
| Dec 31, 1992 | 84,900 | 2,200 | 2.66% |
| Dec 31, 1991 | 82,700 | 500 | 0.61% |
| Dec 31, 1990 | 82,200 | -900 | -1.08% |
| Dec 31, 1989 | 83,100 | 1,800 | 2.21% |
| Dec 31, 1988 | 81,300 | 3,100 | 3.96% |
| Dec 31, 1987 | 78,200 | 1,100 | 1.43% |
| Dec 31, 1986 | 77,100 | 2,200 | 2.94% |
| Dec 31, 1985 | 74,900 | 700 | 0.94% |
| Dec 31, 1984 | 74,200 | -3,200 | -4.13% |
| Dec 31, 1983 | 77,400 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
| Eli Lilly and Company | 50,000 |
JNJ News
- 3 days ago - 3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026 - TipRanks
- 4 days ago - Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push - TipRanks
- 4 days ago - Johnson & Johnson invests more than $1B in Jacksonville, Florida - TheFly
- 4 days ago - Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida - Business Wire
- 6 days ago - New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma - GlobeNewsWire
- 6 days ago - New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma - PRNewsWire
- 8 days ago - Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL - TheFly
- 8 days ago - Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients - Business Wire